WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018100403) COMBINATION OF PARSTATIN 1-26 AND EXENATIDE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/100403    International Application No.:    PCT/GR2017/000068
Publication Date: 07.06.2018 International Filing Date: 04.12.2017
IPC:
A61K 38/17 (2006.01), A61K 38/26 (2006.01), A61P 9/10 (2006.01)
Applicants: UNIVERSITY OF PATRAS [GR/GR]; 26504 Rio Patras (GR).
TSOPANOGLOU, Nikolaos [GR/GR]; (GR).
MARAGOUDAKIS, Michael [GR/GR]; (GR)
Inventors: TSOPANOGLOU, Nikolaos; (GR).
MARAGOUDAKIS, Michael; (GR)
Agent: CHANDANOU, Alexandra; 11 K. Varnali Str. 152 33 Athens (GR)
Priority Data:
20160100618 02.12.2016 GR
Title (EN) COMBINATION OF PARSTATIN 1-26 AND EXENATIDE
(FR) COMBINAISON DE PARSTATINE 1-26 ET D'EXÉNATIDE
Abstract: front page image
(EN)The present invention provides a combination comprising (i) parstatin peptide 1 - 26, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof; and (ii) exenatide, or a functional derivative or analogue, or a pharmaceutically acceptable salt thereof. Said combination is suitable for cardioprotection and for treating and/or preventing ischemia and/or reperfusion injury. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same.
(FR)La présente invention concerne une combinaison comprenant (i) un peptide de parstatine 1-26, ou un dérivé ou un analogue fonctionnel, ou un sel pharmaceutiquement acceptable de celui-ci; et (ii) un exénatide, ou un dérivé ou analogue fonctionnel, ou un sel pharmaceutiquement acceptable de celui-ci. Cette combinaison est utile pour la cardioprotection et pour le traitement et/ou la prévention de l'ischémie et/ou des lésions de reperfusion. D'autres aspects de l'invention concernent des produits et des compositions pharmaceutiques comprenant lesdites combinaisons selon l'invention, ainsi que des méthodes de traitement les utilisant.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)